{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:28:26Z","timestamp":1784906906955,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijantimicag.2016.04.014","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T14:03:23Z","timestamp":1463061803000},"page":"56-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections"],"prefix":"10.1016","volume":"48","author":[{"given":"Michael P.","family":"Veve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/AAC.01896-13","article-title":"Contemporary diversity of \u03b2-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime\u2013avibactam activity tested against isolates producing the most prevalent \u03b2-lactamase group","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0015","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1086\/320182","article-title":"Variations in the prevalence of strains expressing an extended-spectrum \u03b2-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region","volume":"32","author":"Winokur","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.diagmicrobio.2005.10.001","article-title":"Prevalence and antimicrobial susceptibility data for extended-spectrum \u03b2-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997\u20132004)","volume":"53","author":"Goossens","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkm310","article-title":"Antimicrobial susceptibility among organisms from the Asia\/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline","volume":"60","author":"Reinert","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0030","first-page":"625170","article-title":"ESBLs: a clear and present danger?","volume":"2012","author":"Dhillon","year":"2012","journal-title":"Crit Care Res Pract"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","article-title":"Extended-spectrum \u03b2-lactamase-producing organisms","volume":"73","author":"Falagas","year":"2009","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1345\/aph.1Q473","article-title":"Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum \u03b2-lactamase producing Gram-negative bacteria","volume":"46","author":"Fong","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0050","first-page":"459","article-title":"Managing an outpatient parenteral antibiotic therapy team: challenges and solutions","volume":"10","author":"Halilovic","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/598244","article-title":"Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns","volume":"30","author":"Hussein","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0060","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0065","author":"Forest Pharmaceuticals Inc."},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000472866","article-title":"The trometamol salt of fosfomycin: microbiological evaluation","volume":"13","author":"Greenwood","year":"1987","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0075","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","article-title":"Fosfomycin for the treatment of resistant Gram-negative bacterial infections","volume":"34","author":"Reffert","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01877485","article-title":"Urinary concentrations of fosfomycin after a single 3\u2009g dose of fosfomycin to elderly nursing-home patients","volume":"16","author":"Janknegt","year":"1994","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0095","series-title":"Performance standards for antimicrobial susceptibility testing; twentieth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0100","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0105","series-title":"Prevention of hospital-acquired infections: a practical guide","author":"Ducel","year":"2002"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum \u03b2-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0115","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"168","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum \u03b2-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0125","author":"Center for Drug Evaluation and Research, Food and Drug Administration"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3346\/jkms.2012.27.5.476","article-title":"Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial","volume":"27","author":"Park","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0135","series-title":"IDSA comments on FDA draft guidance on developing drugs for complicated urinary tract infections (cUTI)","author":"Slama","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0140","first-page":"551","article-title":"A new strategy to fight antimicrobial resistance: the revival of old antibiotics","volume":"20","author":"Cassir","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0145","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijantimicag.2015.09.008","article-title":"In vitro activity of \u2018old antibiotics\u2019 against highly resistant Gram-negative bacteria","volume":"46","author":"Dubourg","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.04.014_bib0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:39:21Z","timestamp":1534415961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916300929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0924857916300929"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}